scholarly journals Equine Influenza and Tetanus Immunisation: Evaluation of Antibody Response and Safety of Equip® FT and Equip® F Administration after Reduction of the Primary Course Interval to 3 Weeks

2013 ◽  
Vol 45 ◽  
pp. 17-17
Author(s):  
R. Paillot ◽  
E. Ons ◽  
B. Besognet ◽  
N. Slootmans ◽  
A. Thomas ◽  
...  
Keyword(s):  
Antibody Response ◽  
Equine Influenza ◽  
Tetanus Immunisation

scholarly journals Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage

Vaccines ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 174 ◽  
Author(s):  
Fougerolle ◽  
Fortier ◽  
Legrand ◽  
Jourdan ◽  
Marcillaud-Pitel ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Antibody Response ◽  
Large Scale ◽  
Vaccine Coverage ◽  
Natural Infection ◽  
Equine Influenza Virus ◽  
Surveillance Network ◽  
Equine Influenza ◽  
Geographical Regions ◽  
Clade 1

Every year, several epizooties of equine influenza (EI) are reported worldwide. However, no EI case has been identified in France between 2015 and late 2018, despite an effective field surveillance of the pathogen and the disease. Vaccination against equine influenza virus (EIV) remains to this day one of the most effective methods to prevent or limit EI outbreaks and the lack of detection of the pathogen could be linked to vaccination coverage. The aim of this study was to evaluate EI immunity and vaccine coverage in France through a large-scale serological study. A total of 3004 archived surplus serums from French horses of all ages, breeds and sexes were selected from four different geographical regions and categories (i.e., sanitary check prior to exportation, sale, breeding protocol or illness diagnosis). EIV-specific antibody response was measured by single radial hemolysis (SRH) and an EIV-nucleoprotein (NP) ELISA (used as a DIVA test). Overall immunity coverage against EIV infection (i.e., titers induced by vaccination and/or natural infection above the clinical protection threshold) reached 87.6%. The EIV NP ELISA results showed that 83% of SRH positive serum samples from young horses (≤3 years old) did not have NP antibodies, which indicates that the SRH antibody response was likely induced by EI vaccination alone (the HA recombinant canarypoxvirus-based EI vaccine is mostly used in France) and supports the absence of EIV circulation in French horse populations between 2015 and late 2018, as reported by the French equine infectious diseases surveillance network (RESPE). Results from this study confirm a strong EI immunity in a large cohort of French horses, which provides an explanation to the lack of clinical EI in France in recent years and highlights the success of vaccination against this disease. However, such EI protection has been challenged since late 2018 by the incursion in the EU of a Florida Clade 1 sub-lineage EIV (undetected in France since 2009), which is also reported here.

scholarly journals Neutralization antibody response to booster/priming immunization with new equine influenza vaccine in Japan

2018 ◽  
Vol 80 (2) ◽  
pp. 382-386 ◽  
Author(s):  
Takashi YAMANAKA ◽  
Manabu NEMOTO ◽  
Hiroshi BANNAI ◽  
Koji TSUJIMURA ◽  
Tomio MATSUMURA ◽  
...  
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Equine Influenza

scholarly journals Response of Sport Horses to Different Formulations of Equine Influenza Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 372
Author(s):  
Johanna Entenfellner ◽  
Jacinta Gahan ◽  
Marie Garvey ◽  
Cathal Walsh ◽  
Monica Venner ◽  
...  
Keyword(s):  
Antibody Response ◽  
Booster Vaccination ◽  
Recombinant Vaccine ◽  
Delayed Response ◽  
Recombinant Vaccines ◽  
Post Vaccination ◽  
Equine Influenza ◽  
Injection Site Reactions ◽  
Significant Difference ◽  
Antibody Titres

The international governing body of equestrian sports requires that horses be vaccinated against equine influenza within 6 months and 21 days of competing. The aim of this study was to compare the antibody response of young sport horses to six-monthly booster vaccination with equine influenza vaccines of different formulations. An inactivated vaccine was allocated to 35 horses and subunit and recombinant vaccines were allocated to 34 horses each. After vaccination, all horses were monitored for evidence of adverse reactions. Whole blood samples were collected at the time of vaccination and on nine occasions up to six months and 21 days post vaccination. Antibodies against equine influenza were measured by single radial haemolysis. Transient fever and injection site reactions were observed in several horses vaccinated with each vaccine. Only two horses failed to seroconvert post booster vaccination but there was a delayed response to the recombinant vaccine. The antibody response to the recombinant vaccine was lower than that induced by the whole-inactivated and subunit vaccines up to three months post vaccination. Thereafter, there was no significant difference. By six months post vaccination, the majority of horses in all three groups were clinically but not virologically protected. There was minimal decline in antibody titres within the 21-day grace period.

Zostavax Elicits Antibody Response in Younger Group

2007 ◽  
Vol 37 (11) ◽  
pp. 24
Author(s):  
MIRIAM E. TUCKER
Keyword(s):  
Antibody Response
Sign in / Sign up

Export Citation Format

Share Document